SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on April 12, 2013. The registrant is incorporated in Delaware and maintains its principal executive offices in Solana Beach, California. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this Form 8-K. The document solely references the attachment of a management presentation.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The filing discloses a presentation (Exhibit 99.1) used by management in meetings to describe the Company.
Legal Status of Information: The information contained in Item 7.01 and Exhibit 99.1 is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. Consequently, no specific guidance, outlook, or risk factors are detailed in the body of this report.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Presentation dated April 2013) for actual business updates, as the 8-K text only references its existence.
- Confirm that the presentation is not legally "filed" and therefore does not carry the same liability protections as a standard SEC filing.
- Note the discrepancy between the request metadata ("HARROW, INC.") and the actual registrant name in the document ("IMPRIMIS PHARMACEUTICALS, INC.").